Introduction
============

Atypical teratoid rhabdoid tumor (ATRT) is a rare and highly aggressive embryonal tumor of the central nervous system with a dismal prognosis ([@B5]). Because the tumor is so rare and randomized controlled trials are so few, there is no consensus on optimal treatment for children with ATRT. Different multimodal strategies consisting of surgery, chemotherapy, and radiation therapy are currently being used in an attempt to improve outcomes ([@B7]).

A recent review of the US Cancer Database from 2004 to 2012 shows that trimodality therapy seems to offers the best outcome ([@B6]). Another review of the literature points out high dose chemotherapy with stem cell rescue and radiotherapy as the two key components associated with improved outcome in children and adolescents with newly diagnosed ATRT ([@B15]). For patients with localized disease who received trimodality therapy, the overall survival rate at 5 years approaches 50% ([@B6]). But the outcome remains poor for children with a metastatic disease, bringing down the 5-years overall survival rate to 30%, and for children younger than 3 years old who are less likely to receive radiation therapy in regard to potential long term neurocognitive sequelae.

Metronomic chemotherapy (MC) is an emerging alternative approach to conventional chemotherapy, relying on more frequent and low-dose drug administrations with minimal drug-free breaks. It is a multi-targeted therapy which targets tumor angiogenesis, increases the anticancer immune response and induces tumor dormancy ([@B10]; [@B2]). MC is frequently associated with drug repositioning to generate what has been defined as metronomics ([@B1]).

Herein, we report a case of refractory metastatic ATRT which was successfully put into sustained complete remission with metronomics.

Case Presentation
=================

The patient, an 8-year-old boy without significant past medical history, presented with seizures in October 2015. Initial magnetic resonance imaging (MRI) examination revealed a heterogeneously enhanced solid and cystic mass with hemorrhagic areas in the left frontal cortex. The solid part of the tumor showed isointense signal with heterogeneous enhancement on T1-weighted images and slightly hyperintensity on T2-weighted images. There was MRI evidence of tumor in the intracranial leptomeninges at diagnosis. On admission, a partial tumor resection was performed. Pathologic diagnosis of ATRT grade IV of the World Health Organization (WHO) was confirmed by immunohistochemistry demonstrating loss of nuclear expression of INI1. No malignant cell was found into the cerebro-spinal fluid (CSF).

Because of the aggressive nature of the tumor a second surgery for further resection was performed on admission day 20. Chemotherapy was then started. The patient received two courses of chemotherapy with vincristine (1.5 mg/m^2^ D1), cyclophosphamide (800 mg/m^2^ D1--D3), and doxorubicin (30 mg/m^2^ D1, D2) but he progressed rapidly. In December 2015, the patient presented with clinical neoplastic meningitis, confirmed by identification of circulating tumor cells in the CSF and leptomeningeal enhancement with no local evolution of the tumor on the brain and spinal MRI. Patient received a second line of chemotherapy consisting in cisplatin (20 mg/m^2^ D1--D5), etoposide (100 mg/m^2^ D1--D3), and ifosfamide (1.5 g/m^2^ D1--D5) while waiting for radiation therapy. Radiation therapy was started 2 weeks later with a craniospinal irradiation of 36 Gy and a focal boost of 54 Gy. The follow-up MRI a month after the end of radiotherapy was clear. Patient received a second course of chemotherapy consisting in cisplatin, etoposide, and ifosfamide. In April 2016, the patient relapsed with neoplastic meningitis and presented headaches and mild alteration of consciousness MC was started right away according to the MEMMAT-derived protocol ([@B11]; [@B12]) without thalidomide and intrathecal etoposide (**Table [1](#T1){ref-type="table"}**).

###### 

Metronomic chemotherapy regimen: dosing schedule.

  Bevacizumab            10 mg/kg     Intravenous   Days 1, 15
  ---------------------- ------------ ------------- ---------------------------
  Liposomal cytarabine   35 mg        Intrathecal   Day 1
  Celecoxib              400 mg       Oral          Continuous
  Cyclophosphamide       2.5 mg/kg    Oral          Alternating 21 day cycles
  Etoposide              50 mg/m^2^                 
                                                    

Symptoms rapidly subsided. MRI showed regression of the leptomeningeal enhancement a month after starting therapy and cleared up at month 4 (**Figure [1](#F1){ref-type="fig"}**). No circulating tumor cells could be found in the CSF any longer.

![Timeline of diagnosis and treatment.](fphar-08-00792-g001){#F1}

To date, the patient has received 10 months of MC. As for toxicity associated with the metronomic chemotherapy the patient exhibited moderate asthenia, 2 chemotherapy-induced reversible grade 4 neutropenia, type A influenza, and 2 reversible local reactions at the site of injection of intrathecal chemotherapy. No transfusion were necessary.

He has had no complaints and has resumed normal activities, including going to school and participating in physical education. At last follow up, brain and spinal MRI is clear (**Figure [2](#F2){ref-type="fig"}**) and so is CSF examination. We plan to keep him on treatment for 12 months.

![Spine MRI before and after 7 months of metronomic chemotherapy. MRI evidence of disseminated leptomeningeal tumor in pre-treatment T1-weighted gadolinium enhanced sagittal view **(A)** disappeared after 7 months of metronomic chemotherapy **(B)**.](fphar-08-00792-g002){#F2}

Discussion
==========

More clinical experience of MC in pediatric oncology has been gained over the past few years ([@B10]; [@B2]). [@B12] reported the results of a multidrug combination regimen in 16 patients with recurrent embryonal brain tumors, including three ATRT. The regimen included continuous oral celecoxib, thalidomide, and fenofibrate with alternating metronomic etoposide and cyclophosphamide, in combination with biweekly bevacizumab, with or without intrathecal chemotherapy. All three patients with ATRT were alive at 42, 12, and 10 months after their last recurrence/progression; one showed initial partial response, one had stable disease and one had no evidence of disease after surgery.

[@B14] presented data from a phase II 5-drug oral regimen in 101 patients with recurrent or progressive cancer, including two ATRT. Treatment consisted of MEMMAT without bevacizumab and intrathecal therapy. Clinical benefit was seen in patients with low-grade glioma and ependymoma, as well as in the miscellaneous stratum which included the two patients with ATRT. Specific results for these patients were not reported. Elsewhere, [@B8] have reported the response of a relapsing spinal ATRT to a metronomic combination of vinorelbine, cyclophosphamide, and celecoxib further confirming the potential of metronomics in this disease. Lastly, metronomics may also be useful when used as maintenance treatment ([@B9]) as reported by [@B4] with high risk pediatric brain tumors including ATRT. Anyhow, while we do not know yet which kind of tumors a good candidate for a metronomic approach and in which setting (relapse, maintenance, radiation therapy sensitization), it is now admitted that different tumors may require different metronomic treatment ([@B2]).

Metronomic chemotherapy is generally well-tolerated in trials, with reports of predominantly mild toxicities. But careful patient selection is key; a recent study exploring the effect of metronomic thalidomide, etoposide, and celecoxib in children with various refractory or high risk tumor showed an improvement in quality of life measured by the Karnofsky-Lansky scores, although the majority of patients declared grades III--V adverse effects ([@B13]). The most common adverse effect observed is hematological toxicities, such as neutropenia that our patient exhibited. The absence of thalidomide in the regimen we used protected the patient from an increased risk of neurological toxicity. Besides, we decided to omit intrathecal etoposide since the patient, it would have required the insertion of an Omaya reservoir which was judged to be too invasive. Further investigations are warranted regarding potential long-term toxicities.

How the metronomics combination have led to achievement of a complete response in a refractory/relapsing disease can only be speculative and surely rely on several mechanisms. Indeed, MC has been reported to be able to inhibit angiogenesis as well as restore the anticancer properties of the immune system ([@B10]; [@B2]). Moreover, recently, the potential of MC to directly kill cancer cells has been highlighted ([@B3]). More specifically, intrathecal liposomal aracytine may have contributed to directly kill metastatic meningeal tumors cells for which inhibition of angiogenesis does not seem to be efficient since thin layers of tumors cells may not depend upon angiogenesis for survival ([@B12]).

Concluding Remarks
==================

Long term and high volume trials of metronomic chemotherapy in ATRT are not available. We offer experience in a complete and sustained clinical-radiological response to MC in a case of early-relapsing ATRT.
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